The U.S. Food and Drug Administration (FDA) has approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab), for the treatment of multiple chronic inflammatory diseases, including psoriasis and psoriatic arthritis.
Cyltezo is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Cyltezo is also indicated, alone or in combination with traditional disease-modifying antirheumatic drugs, or DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
The biosimilar, which is manufactured by Boehringer Ingelheim Pharmaceuticals, is administered with a pre-filled syringe. The company is also seeking approval for an auto-injector.
Cyltezo is not commercially available at this time due to pending litigation.
Read more about biosimilars.
Driving Discovery, Creating Community
This year, we’re celebrating 50 years of driving efforts to cure psoriatic disease and improve the lives of those affected. See how far we’ve come with this timeline of NPF’s history. But there’s still plenty to do, and we can’t do it without you! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funding to promote research into better treatments and a cure by joining Team NPF, where you can walk, run, cycle, play bingo or even create your own DIY event. Contact our Patient Navigation Center for free, personalized support for living a healthier life with psoriatic disease. And keep the National Psoriasis Foundation going strong by making a donation today! Together, we will find a cure.